Menu

Home / Guides / FEHB GLP-1 coverage 2027

OPM’s 2027 rule, explained.

FEHB GLP-1 Coverage in 2027: The New Behavioral Therapy Rule and What You’ll Pay

By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated

For 2027, FEHB and PSHB plans keep covering at least one weight-loss GLP-1 but will require documented behavioral therapy, OPM says. Your cost depends on your plan’s tier: 25% to 60% coinsurance on covered brand tiers, or a copay on some plans (FedTools). Open Season ends December 14, 2026. Without coverage, compounded tirzepatide through NexLife is $115 a month on the 12-month plan, or $129 month to month.

  • OPM’s rule: documented behavioral therapy before and during treatment
  • Open Season: November 9 to December 14, 2026
  • FEP Blue’s 2027 Standard and Basic drug lists: Wegovy Tier 3; Zepbound not covered
Published by NexLifeLegitScript-certified
NexLifeSame price at every dose
Illustration of a compounded tirzepatide vial

$115/mo on a 12-month plan, all-inclusive, same price at every dose

Or $129/mo month to month

Self-pay, with no membership fee. A licensed provider decides if it’s right for you

Check my eligibility

About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication

See all 4 plans and what a year costs
Compounded tirzepatide, all in, the same price at every dose
PlanPer month12 months at this rate
12-month Most savings$115$1,380
6-month$119$1,428
3-month$125$1,500
Month to month$129$1,548

Month to month costs $168 more over 12 months than the 12-month plan. Plans renew until you cancel. Month to month is billed monthly. The 3-, 6- and 12-month plans are paid upfront at checkout: $375, $714 or $1,380.

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026)LegitScript-certified

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.

  • Licensed U.S. providers
  • LegitScript certified
  • Free expedited shipping
  • HSA, FSA, Affirm, Klarna, Afterpay
  • 24/7 support, real people
  • Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)

Compounded tirzepatide and semaglutide aren’t FDA-approved and aren’t Zepbound or Wegovy. A licensed provider prescribes them only when they offer a significant difference for you.

The short version

FEHB GLP-1 coverage in 2027 at a glance: rule, cost and dates

FEHB and PSHB GLP-1 coverage in 2027 at a glance: OPM’s rule, therapy sessions, what you pay, FEP Blue’s drug lists, Open Season dates and the self-pay option, from OPM (re-checked Nov. 12, 2026), FEP Blue and FedTools (read November 1, 2026)
QuestionAnswer
Does FEHB cover GLP-1s in 2027?Yes, OPM says: every FEHB and PSHB plan must cover at least one weight-loss GLP-1, with documented behavioral therapy before and during treatment.
How many therapy sessions?Plans should cover 12 to 22 a year, depending on progress, plus medical nutrition therapy (OPM).
What will you pay?It depends on your plan: 25% to 60% coinsurance on covered brand tiers in OPM’s 2027 plan file, a FedTools review found; some plans use copays.
Wegovy or Zepbound?FEP Blue Standard and Basic, 2027 drug lists: Wegovy on Tier 3 with prior approval; Zepbound not covered. FEP Blue Focus lists neither.
When is Open Season?November 9 to December 14, 2026. Changes start January 1, 2027 for PSHB enrollees and annuitants, January 10 for FEHB employees outside the Postal Service.
Paying yourself instead?Compounded tirzepatide at NexLife: $115 a month on the 12-month plan or $129 month to month, at every dose. Not FDA-approved; NexLife doesn’t bill FEHB plans.

From OPM’s 2027 Open Season highlights (re-checked Nov. 12, 2026), FEP Blue’s 2027 drug lists (read November 1, 2026) and a FedTools review of OPM’s plan file. NexLife’s prices from our plan page.

  1. Tell us about you About 3 minutes of health questions
  2. A licensed provider decides You’re prescribed only if it’s right for you
  3. Your partner pharmacy ships Usually within 1 to 2 business days, free

Key takeaways

  • FEHB and PSHB plans must cover at least one weight-loss GLP-1 in 2027 and will require documented behavioral therapy, OPM says.
  • Plans should cover 12 to 22 therapy sessions a year, depending on progress, plus medical nutrition therapy, OPM says.
  • Your cost depends on your plan’s tier: 25% to 60% coinsurance on covered brand tiers, or a copay on some plans (FedTools).
  • FEP Blue Standard and Basic, 2027: Wegovy on Tier 3 with prior approval; Zepbound not covered (drug lists read November 1, 2026).
  • Open Season runs November 9 to December 14, 2026; the average FEHB premium rises 9.3% for 2027.
  • Paying yourself? Compounded tirzepatide through NexLife, not FDA-approved, is $115 a month on the 12-month plan. NexLife doesn’t bill FEHB.

OPM’s rule

What changes for GLP-1 coverage in FEHB and PSHB plans in 2027?

Coverage continues, with a condition. For 2027, OPM says every FEHB and PSHB plan must still cover at least one GLP-1 and two oral anti-obesity drugs. All carriers will also require documented intensive behavioral therapy before and during treatment. What’s new is that the therapy must be documented. Employer plans are changing too: GLP-1 coverage in 2027.

“Plans will continue to cover at least one GLP-1 anti-obesity medication and at least two oral anti-obesity medications. For 2027, all FEHB and PSHB Carriers will require documented participation in an evidence-based intensive behavioral therapy (IBT) program both prior to and during treatment with anti-obesity medications.”

U.S. Office of Personnel Management, Federal Benefits Open Season Highlights, 2027 Plan Year

The coverage half isn’t new. Since January 2023, OPM has required carriers to cover at least one GLP-1 for weight loss and two more oral options, its inspector general notes. In January 2025, OPM reminded carriers that behavioral therapy should go with any drug treatment of obesity. What’s new for 2027 is that the therapy must be documented.

When does 2027 FEHB coverage start?

It depends on who you are, OPM’s Open Season highlights list. PSHB enrollees and annuitants start January 1, 2027. FEHB employees outside the Postal Service start January 10, 2027, and compensationers (OWCP) January 24, 2027. FSAFEDS and FEDVIP elections take effect January 1, 2027. A cancellation takes effect the day before each date.

Effective dates for Open Season enrollment changes, as OPM’s 2027 Open Season highlights list them, checked Nov. 12, 2026. FSAFEDS and FEDVIP elections take effect January 1, 2027.
If you areOpen Season changes take effectA cancellation takes effect
An FEHB employeenot Postal ServiceJanuary 10, 2027January 9, 2027
An FEHB compensationerOWCPJanuary 24, 2027January 23, 2027
A PSHB enrolleePostal ServiceJanuary 1, 2027December 31, 2026
An annuitantJanuary 1, 2027December 31, 2026

Swipe the table sideways to see every column.

Effective dates for Open Season enrollment changes, as OPM’s 2027 Open Season highlights list them, checked Nov. 12, 2026. FSAFEDS and FEDVIP elections take effect January 1, 2027.

Behavioral therapy

What counts as intensive behavioral therapy, and how many sessions?

An evidence-based program, documented, before you start a weight-loss drug and while you take it. OPM expects plans to cover individual and group intensive behavioral therapy and medical nutrition therapy, with 12 to 22 therapy sessions a year depending on progress. Each plan names its own programs, such as Compass Rose’s $0 program with TrestleTree.

The details
What OPM requiresDocumented participation in an evidence-based intensive behavioral therapy (IBT) program, before and during treatment with anti-obesity medicines
What plans should coverIndividual and group intensive behavioral therapy and medical nutrition therapy, including 12 to 22 therapy sessions a year, depending on progress
How it fits the drug rulesCarriers must coordinate it with their medication and metabolic-surgery criteria
Who it applies toWeight-loss use, FedSmith reports. GLP-1s prescribed for diabetes follow your plan’s diabetes drug rules
Children and teensPlans must also cover qualifying programs for ages 6 and up with a BMI above the 95th percentile: 26 or more contact hours over 3 to 12 months

Already taking a GLP-1?

The rule covers treatment already under way: OPM says “during” as well as “prior to.” Compass Rose, for one, says members who already use a GLP-1 for weight loss must join its program to keep coverage. Ask your plan which programs count, how participation is documented, and when you need to start.

What does a behavioral therapy program look like?

Plans name their own. Compass Rose’s 2027 program is a Weight Loss & Lifestyle Management program run with TrestleTree, at $0 to members. FEP Blue’s 2027 brochure lists unlimited nutritional counseling and unlimited individual and group behavioral counseling for obesity (both read November 1, 2026).

Your cost

Will your GLP-1 copay or coinsurance change in 2027?

It can, and it varies by plan. OPM’s 2027 plan-benefits file shows 25% to 60% coinsurance on covered brand tiers, a FedTools review found (October 21, 2026); some plans use copays instead. Your drug’s tier and its cap decide what you pay. Wegovy’s 2027 prices: Wegovy price in 2027.

  • 25% to 60%coinsurance on covered brand tiers in OPM’s 2027 plan fileFedTools review, October 21, 2026
  • $675Wegovy’s list price from January 1, 2027down from $1,349.02, Novo Nordisk
  • November 6from then on, FEP Blue’s drug cost tool shows 2027 pricesfepblue.org

Is it 50% on every plan? No. A viral claim on Reddit’s r/FedEmployees said every 2027 plan charges 50% for GLP-1s. OPM’s 2027 plan-benefits file, revised October 15, 2026, shows 25% to 60% on covered brand tiers, and some plans use copays instead, a FedTools review found. 50% is real on some tiers of some plans.

Read the cap, not just the percentage. On FEP Blue Basic in 2027, a preferred brand is 35% up to $175 for a 30-day supply, but a non-preferred brand is 60% with no cap. Your drug’s tier decides which one you pay.

Does Wegovy’s lower list price help?

If you pay a percentage, it can. Novo says its cut to $675 on January 1, 2027 is meant for people whose costs are linked to list price, such as those in high-deductible plans or with coinsurance. FEP Blue figures coinsurance as a percentage of its plan allowance, so your share can differ from a percentage of list price.

Can you use the Wegovy savings card with FEHB?

Yes, Novo’s terms say: the FEHB Program isn’t a government health care program for its savings offer. If your plan covers Wegovy, you can pay as little as $25, with savings up to $100 a month (terms read November 15, 2026). People enrolled in Medicare can’t use it.

By carrier

What have FEHB plans announced for GLP-1 coverage in 2027?

As of November 1, 2026, FEP Blue’s 2027 Standard and Basic drug lists put Wegovy on Tier 3 with prior approval. They list Zepbound as not covered, and FEP Blue Focus lists neither. Compass Rose requires its new $0 weight-loss program for GLP-1 coverage. Carriers’ 2027 brochures are now posted on OPM.gov, beside OPM’s Plan Comparison Tool (checked Nov. 15, 2026).

From each carrier’s own 2027 pages, brochure and drug lists, read November 1, 2026: the federal (FEHB) versions; FEP Blue’s Postal (PSHB) documents are separate. FEP Blue’s drug placements come from its 2027 Traditional Drug Lists, the PDFs its formulary page links to, each effective January 1, 2027. Prior approval means your prescriber needs the plan’s OK before it pays.
PlanGLP-1s for weight loss in 2027Source
FEP Blue StandardBlue Cross and Blue Shield Service Benefit PlanIts 2027 drug list: Wegovy pen and pill, and Wegovy HD, Tier 3 (non-preferred brand), prior approval required; Zepbound is in its chart of drugs not covered in 2027, with Wegovy among the covered options. Its brochure: Tier 3 is 50% of the plan allowance at a Preferred retail pharmacy, or 20% up to $250 for up to 90 days through FEP’s mail service pharmacy.FEP Blue Standard Formulary, effective January 1, 2027; 2027 brochure
FEP Blue BasicIts 2027 drug list: Wegovy and Wegovy HD, Tier 3, prior approval required; Zepbound is in its chart of drugs not covered in 2027. Its brochure: Tier 3 is 60% of the plan allowance at a Preferred retail pharmacy.FEP Blue Basic Formulary, effective January 1, 2027; 2027 brochure
FEP Blue FocusIts 2027 drug list: the anti-obesity drugs listed are generic liraglutide and orlistat, Tier 1, prior approval required. Wegovy and Zepbound aren’t on it.FEP Blue Focus Drug Formulary, effective January 1, 2027
FEP Blue, all optionsNew 2027 copays and cost-share maximums for brand, specialty and diabetes drugs. Accredo becomes the specialty pharmacy in January 2027.fepblue.org, What’s new for 2027
Compass RoseStandard and High OptionA new Weight Loss & Lifestyle Management program, at $0, is required for weight-loss GLP-1 coverage, including for people already taking one. Anti-obesity drugs are Tier 3.Compass Rose, October 5, 2026
Compass Rose Medicare AdvantageYou must be enrolled in, and taking part in, an intensive behavioral therapy program to keep GLP-1 weight-loss coverage. Part D out-of-pocket maximum: $2,400.Compass Rose, October 5, 2026

Swipe the table sideways to see every column.

From each carrier’s own 2027 pages, brochure and drug lists, read November 1, 2026: the federal (FEHB) versions; FEP Blue’s Postal (PSHB) documents are separate. FEP Blue’s drug placements come from its 2027 Traditional Drug Lists, the PDFs its formulary page links to, each effective January 1, 2027. Prior approval means your prescriber needs the plan’s OK before it pays.

Premiums

Why are FEHB premiums rising 9.3% in 2027?

Higher medical and drug spending, OPM says, with GLP-1s among the drivers. The average FEHB premium rises 9.3% for 2027 (enrollee share 10.9%) and PSHB 6.7% (8.2%). At two carriers OPM’s inspector general studied, GLP-1s rose from 4% of pharmacy spending in 2019 to 18% in 2024 (December 8, 2025).

  • 9.3%average FEHB premium increase for 2027enrollee share: 10.9%
  • 6.7%average PSHB premium increase for 2027enrollee share: 8.2%
  • 500%+rise in FEHB GLP-1 pharmacy spending from 2019 to 2024at two carriers with 69% of members
  • Rising prices and use of inpatient, physician, outpatient and surgical services
  • Continued growth in behavioral and mental health care
  • Higher prescription drug spending, particularly on GLP-1s, specialty drugs and other high-cost therapies

OPM’s inspector general found that GLP-1s went from 4% of FEHB pharmacy spending in 2019 to 18% in 2024, at the two carriers it studied, which cover 69% of members (December 8, 2025). Semaglutide (Ozempic and Wegovy) made up 64% of GLP-1 claims.

Medicare

How does Medicare affect PSHB and FEHB GLP-1 coverage in 2027?

If you have Medicare Part D, Medicare’s 2027 drug rules apply to you too. PSHB plans include Part D through an employer group waiver plan, and Part D’s out-of-pocket cap rises to $2,400 in 2027, from $2,100. If you qualify, the Medicare GLP-1 Bridge covers Wegovy, Foundayo or the Zepbound KwikPen for $50 a month through December 31, 2027.

PSHB plans include Part D. OPM requires PSHB plans to provide Medicare Part D drug coverage through an employer group waiver plan (EGWP). It generally requires Postal Service annuitants newly entitled to Medicare to enroll in Part B.

Part D’s out-of-pocket cap rises to $2,400 in 2027, from $2,100 (Medicare.gov). FEP Blue’s and Compass Rose’s Medicare drug plans list the same $2,400.

The Medicare GLP-1 Bridge can cover Wegovy (pen or pill), Foundayo or the Zepbound KwikPen for $50 a month through December 31, 2027, with prior authorization, for people with Part D who meet its BMI and health criteria. Employer group plans (EGWPs) count as Part D for the Bridge. You aren’t eligible if your Part D plan already covers a GLP-1 for you, or if you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease.

Savings cards don’t work with Medicare. Novo’s and Lilly’s cards exclude government programs. NovoCare’s self-pay price is open to people with government coverage who choose to pay themselves.

Step by step

How do you get a GLP-1 covered under FEHB in 2027, step by step?

Six steps for Open Season, from your plan’s 2027 drug list to a backup if it won’t pay.

  1. Find your drug on each 2027 list. Check its tier, prior approval and any program rule. FEP Blue Standard and Basic put Wegovy on Tier 3 with prior approval and list Zepbound as not covered.
  2. Document your behavioral therapy. Every carrier will require documented intensive behavioral therapy before and during treatment. Ask your plan which programs count, how participation is documented and when you need to start.
  3. Price a full year. Add premiums to 12 or 13 fills at the plan’s cost share, and read the cap, not just the percentage. On FEP Blue Basic, a non-preferred brand is 60% with no cap.
  4. Use the savings card and FSAFEDS. If your plan covers Wegovy, Novo’s savings card works with FEHB, though not with Medicare. Re-enroll in FSAFEDS by December 14, 2026; it doesn’t carry over.
  5. Choose your plan by December 14. Open Season runs November 9 to December 14, 2026. Changes start January 1, 2027 for PSHB enrollees and annuitants, and January 10 for FEHB employees outside the Postal Service.
  6. Not covered? Price paying yourself. Zepbound vials are $299 to $449 a month at LillyDirect ($449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699). Compounded tirzepatide, not FDA-approved, is $126 to $599 a month in our GLP-1 price index (checked Nov. 15, 2026).

Six steps, from the drug list to a backup plan.

Open Season

FEHB Open Season 2026 checklist: which dates and documents matter?

Open Season runs November 9 to December 14, 2026. FEP Blue’s drug cost tool shows 2027 prices from November 6, 2026. Re-enroll in FSAFEDS by December 14, 2026 if you want an FSA in 2027; it doesn’t carry over. Adding a family member? OPM now requires documents proving their eligibility.

  1. Carriers’ 2027 brochures and OPM’s Plan Comparison Tool are on OPM.gov. PSHB members compare plans in the Postal Service Health Benefits System (PSHBS).

  2. FEP Blue’s drug cost tool shows 2027 prices.

  3. Open Season opens. Look up your drug on each plan’s 2027 drug list: its tier, prior approval and any program rule.

  4. Price a full year: premiums plus 12 or 13 fills at the plan’s cost share. Adding a family member? New for 2027, OPM requires documents that prove their eligibility.

  5. Re-enroll in FSAFEDS if you want an FSA in 2027: it doesn’t carry over. The FSAFEDS Visa FSA card is new for 2027. Open Season closes.

  6. Changes take effect: January 1 for PSHB enrollees and annuitants, January 10 for non-Postal employees.

In a plan that’s ending? Nine FEHB plan options end after 2026. If you don’t choose a new one, OPM moves you to Compass Rose Standard. One PSHB option ends too; its default is FEP Blue Focus.

Paying yourself

What if your plan stops covering your GLP-1?

You can pay yourself at the makers’ self-pay prices (read November 1, 2026). Zepbound vials are $299 to $449 a month at LillyDirect; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Through NovoCare, the Wegovy pen is $349 and the Wegovy pill $149 to $299. Compounded tirzepatide, which isn’t FDA-approved, costs $126 to $599 a month, month to month and all in, with a median of $285 across the 25 programs that publish a month-to-month price (checked Nov. 15, 2026).

Self-pay prices from LillyDirect, Lilly’s savings-card terms and NovoCare’s terms, read November 1, 2026: the medication alone, with your prescriber’s visit extra. Compounded prices from our GLP-1 price index. Compounded tirzepatide and semaglutide aren’t FDA-approved, aren’t Zepbound or Wegovy, and weren’t studied in those brands’ trials.
OptionA monthGood to know
Zepbound vials at LillyDirect4 vials a month$299 to $449$449 from 7.5 mg if you refill within 45 days; $499 to $699 if not. No end date listed. The KwikPen is the same price today, through a Lilly self-pay card whose terms end December 31, 2026
Wegovy pen through NovoCare0.25 to 2.4 mg$349$399 for Wegovy HD. New patients: $199 for each of their first two fills (through Dec. 31, 2026), with the prescription written and received by that date
Wegovy pill through NovoCare30 tablets$149 to $299By dose
Compounded tirzepatideonline programs; not FDA-approved$126 to $599Month to month, all in: median $285 across 25 programs, checked Nov. 15, 2026
Compounded tirzepatide at NexLife$115 or $129$115 a month on the 12-month plan (paid upfront: $1,380), or $129 month to month (billed monthly); the same at every dose

Swipe the table sideways to see every column.

Self-pay prices from LillyDirect, Lilly’s savings-card terms and NovoCare’s terms, read November 1, 2026: the medication alone, with your prescriber’s visit extra. Compounded prices from our GLP-1 price index. Compounded tirzepatide and semaglutide aren’t FDA-approved, aren’t Zepbound or Wegovy, and weren’t studied in those brands’ trials.

NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works

The makers’ self-pay rules. Novo’s self-pay terms say you can’t bill your plan for these purchases or count them toward a deductible.

At NexLife, compounded tirzepatide is $115 a month on the 12-month plan, $119 (6-month), $125 (3-month) or $129 month to month. Compounded semaglutide is $95 a month on the 12-month plan, $99 (6-month), $105 (3-month) or $109 month to month. Both are the same price at every dose, with no membership fee. NexLife doesn’t bill FEHB or PSHB plans.

How it’s billed: month to month is billed once a month. The 3-, 6- and 12-month plans are paid upfront, in full, at checkout: $375, $714 or $1,380 for tirzepatide, and $315, $594 or $1,140 for semaglutide. A longer plan starts only if you’re prescribed.

Ways to pay: NexLife takes HSA and FSA cards and provides a letter of medical necessity if your plan asks for one. Affirm, Klarna or Afterpay are offered at checkout; approval is theirs to give.

A licensed provider decides whether compounded tirzepatide or semaglutide is right for you, after reviewing your health history and the dose you take now. The labels pair these medicines with a reduced-calorie diet and more physical activity: here’s what to eat on a GLP-1. Questions? Call or text (949) 818-8000, 24/7.

Every program

What do online programs charge for compounded tirzepatide and semaglutide?

Compounded tirzepatide runs $126 to $599 a month and compounded semaglutide $87 to $399, month to month and all in, in our GLP-1 price index (checked Nov. 15, 2026). Neither is FDA-approved. The medians are $285 and $199.

Compounded tirzepatide and semaglutide in our GLP-1 price index, month to month and all in (medication plus any required membership or program fee), checked Nov. 15, 2026
In our indexCompounded tirzepatideCompounded semaglutide
Month-to-month range ($ a month, all in)$126 to $599$87 to $399
Median ($ a month)$285$199
Programs that publish a month-to-month price2527
Lowest month-to-month priceMondae, $126Mondae, $87
Same price at every dose14 of the 2514 of the 27
Programs in the index’s table4444

NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works

How NexLife compares. NexLife, which publishes this guide, charges $129 month to month for compounded tirzepatide, $156 under that median, and $109 for semaglutide, $90 under it. It charges the same at every dose, as 14 of the 25 tirzepatide programs and 14 of the 27 semaglutide programs do.

Not every program shows a price. 18 of the 43 programs selling injectable compounded tirzepatide publish no month-to-month price, so the medians count only the ones that do.

All in means the medication plus any required membership or program fee. Every program, its price and its notes: our GLP-1 price index, checked Nov. 15, 2026. How we read each program’s price: our review methodology.

In their words

What do CMS, the FDA and the label say about GLP-1s for FEHB members?

Three primary sources beside OPM’s rule: the label on lifestyle changes, Medicare’s Bridge and compounded medicines.

In January 2025, OPM reminded carriers that behavioral therapy should go with any drug treatment of obesity; the labels make a similar pairing:

“Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026

PSHB plans include Part D through an employer group waiver plan, so if you’re on Medicare, the Bridge may apply:

“The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.”

Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge

If your plan won’t cover a GLP-1 and you pay yourself, know what a compounded medicine is and isn’t:

“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”

U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers

Vial math

How many units is your tirzepatide or semaglutide dose?

On a compounded vial, the units depend on its strength. Here are the label doses at example strengths, with the math to check your own.

Tirzepatide

Tirzepatide doses on Zepbound’s label, with the volume and units on a U-100 syringe at an example strength of 25 mg per mL; your vial’s label decides
DosemL at 25 mg/mLUnits (U-100)On the label
2.5 mg0.1 mL10 unitsStarting dose, for 4 weeks
5 mg0.2 mL20 unitsA maintenance dose
7.5 mg0.3 mL30 unitsA step up
10 mg0.4 mL40 unitsA maintenance dose
12.5 mg0.5 mL50 unitsA step up
15 mg0.6 mL60 unitsThe maximum, and a maintenance dose

The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.

Semaglutide

Semaglutide dose steps from the Wegovy label, with the volume and units on a U-100 syringe at two example strengths, 2.5 mg/mL and 5 mg/mL
WeeksWeekly doseAt 2.5 mg/mLAt 5 mg/mL
1 to 40.25 mg0.1 mL (10 units)0.05 mL (5 units)
5 to 80.5 mg0.2 mL (20 units)0.1 mL (10 units)
9 to 121 mg0.4 mL (40 units)0.2 mL (20 units)
13 to 161.7 mg0.68 mL (68 units)0.34 mL (34 units)
17 onward2.4 mg0.96 mL (96 units)0.48 mL (48 units)

The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.

25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide and semaglutide dosage calculator. Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. Every step: the semaglutide dosage chart.

What does NexLife cost?
One flat price at every dose.

No membership fee. Provider care, a nutrition plan, coaching and shipping are included.

Illustration of a compounded tirzepatide vialGIP + GLP-1

12-month plan $115/mo

Tirzepatide

Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Illustration of a compounded semaglutide vialGLP-1

12-month plan $95/mo

Semaglutide

Weekly GLP-1. Care, coaching and shipping included. On a 12-month plan, $1,140 paid upfront; $109/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms

Loved by our members

Real stories from NexLife members about their care and service.

A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.

★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗

  • ★★★★★Read on Trustpilot ↗

    “That’s a real site with good prices and plans!”

    Estefany L.

  • ★★★★★Read on Trustpilot ↗

    “Affordable, quick and easy. They could not have made it a smoother less stressful experience.”

    Andisheh K.

  • ★★★★★Read on Trustpilot ↗

    “Great communication. Easy to work with. They work to set you up for success.”

    Anthony C.

  • ★★★★★Read on Trustpilot ↗

    “Fast delivery and easy to get a hold of when needing to talk with someone!”

    Browneyes

  • ★★★★★Read on Trustpilot ↗

    “So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”

    April

  • ★★★★★Read on Trustpilot ↗

    “Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”

    Ethan B.

  • ★★★★★Read on Trustpilot ↗

    “Fast service great communication!! Willing to work with you!”

    Bon

  • ★★★★★Read on Trustpilot ↗

    “Great service and excellent communication!”

    Gabrielle D.

  • ★★★★★Read on Trustpilot ↗

    “Easy and pricing not bad! Customer service was helpful in answering my questions.”

    Lyndy T.

  • ★★★★★Read on Trustpilot ↗

    “Good experience, great team”

    Mai S.

  • ★★★★★Read on Trustpilot ↗

    “Great communciation and was fast and reliable”

    Kiki

  • ★★★★★Read on Trustpilot ↗

    “Very happy so far”

    Tammy E.

Names are shortened for privacy. Reviews are members’ opinions, not medical advice.

FEHB GLP-1 coverage in 2027: your questions

Fair questions about NexLife

Will my price go up with my dose?
No. You pay the same at every dose.
What if I’m not prescribed?
You aren’t charged for medication.
Can I cancel?
Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
Do I need insurance?
No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.

Does FEHB cover Wegovy or Zepbound in 2027?

In 2027, FEHB and PSHB plans keep covering at least one weight-loss GLP-1 but require documented behavioral therapy before and during treatment (OPM). Which one depends on your plan. FEP Blue’s 2027 Standard and Basic drug lists put Wegovy on Tier 3 with prior approval, and list Zepbound as not covered in 2027.

What is the FEHB behavioral therapy requirement?

For 2027, every FEHB and PSHB carrier will require documented participation in an evidence-based intensive behavioral therapy program before and during treatment with anti-obesity medicines. Plans are expected to cover 12 to 22 sessions a year, depending on progress, plus medical nutrition therapy (OPM).

Does the rule apply if I take a GLP-1 for diabetes?

Not as OPM wrote it: the rule is for anti-obesity medicines, and FedSmith reports it applies to weight-loss use. Diabetes GLP-1s such as Ozempic and Mounjaro follow your plan’s diabetes drug rules, which FEP Blue lists as a separate 2027 change. Ask your plan before Open Season ends December 14, 2026.

Is FEHB GLP-1 coinsurance 50% on every plan in 2027?

No. OPM’s 2027 plan-benefits file shows coinsurance from 25% to 60% on covered brand tiers, and some plans use copays instead (FedTools, October 21, 2026). 50% is real on some tiers: FEP Blue Standard’s Tier 3, where Wegovy sits, is 50% of the plan allowance at a Preferred retail pharmacy.

When is FEHB Open Season 2026?

November 9 to December 14, 2026. Changes take effect January 1, 2027 for PSHB enrollees and annuitants, January 10 for FEHB employees outside the Postal Service and January 24 for compensationers (OPM). Re-enroll in FSAFEDS by December 14 if you want an FSA in 2027; it doesn’t carry over.

Why are FEHB premiums going up in 2027?

OPM says the average FEHB premium rises 9.3% and the enrollee share 10.9%, driven by higher medical, mental health and prescription drug spending, particularly on GLP-1s. At the two carriers OPM’s inspector general studied, GLP-1 pharmacy spending rose more than 500% from 2019 to 2024.

Can I use FSAFEDS for GLP-1 costs?

Yes, generally: you can use it for out-of-pocket health costs your FEHB plan doesn’t cover, as long as the expense isn’t for general health or cosmetic reasons (FSAFEDS). You must re-enroll in FSAFEDS every Open Season, and the FSAFEDS Visa FSA card is new for 2027. NexLife provides a letter of medical necessity if your plan asks for one.

Can I use the Wegovy savings card with FEHB?

Yes, if your plan covers Wegovy: Novo’s terms say FEHB isn’t a government program for its savings offer. You can pay as little as $25, with savings up to $100 a month. It isn’t available to people enrolled in Medicare (terms read November 15, 2026).

Does NexLife take FEHB insurance?

No. NexLife is self-pay and doesn’t bill FEHB or PSHB plans: compounded tirzepatide, which isn’t FDA-approved, is $115 a month on the 12-month plan, or $129 month to month, at every dose. You can pay with an HSA or FSA card, and NexLife provides a letter of medical necessity if your plan asks for one.

What happens if my FEHB plan ends after 2026?

If you don’t choose a new one, OPM moves you to Compass Rose Standard, which requires its new $0 weight-loss program for GLP-1 coverage. That applies to the 9 FEHB plan options ending after 2026; for the 1 PSHB option ending, the default is FEP Blue Focus. Choose by December 14, 2026, when Open Season closes.

How much will Wegovy cost on FEP Blue in 2027?

On FEP Blue Standard, Wegovy is Tier 3 with prior approval: 50% of the plan allowance at a Preferred retail pharmacy, or 20% up to $250 for up to 90 days by mail. On FEP Blue Basic, Tier 3 is 60% of the plan allowance at a Preferred retail pharmacy. FEP Blue Focus doesn’t list Wegovy.

Can PSHB members on Medicare use the GLP-1 Bridge?

Yes, if you qualify. PSHB plans include Part D through an employer group waiver plan, and employer group plans count as Part D for the Bridge. It can cover Wegovy (pen or pill), Foundayo or the Zepbound KwikPen for $50 a month through December 31, 2027, with prior authorization.

Important safety information

Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.

Read the full safety information

In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.

Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.

This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.

About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.

Who wrote and medically reviewed this page?

Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine (American Board of Emergency Medicine) · NPI 1144260043

Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.

NexLife Medical TeamWrites and updates NexLife’s guides

OPM’s rules and Open Season dates re-checked Nov. 12, 2026; carrier documents and self-pay prices checked Nov. 1, 2026; compounded prices checked Nov. 15, 2026.

  • How we checked. OPM’s rule, dates, premiums and Open Season facts come from OPM’s 2027 Open Season highlights, re-read Nov. 12, 2026, and the spending figures from OPM’s inspector general. Carrier facts come only from each carrier’s own 2027 pages, brochure and drug lists: FEP Blue and Compass Rose. FedSmith and FedTools explain how the rule and OPM’s plan file read. Self-pay prices are the makers’ own, read Nov. 1, 2026. Medicare’s Bridge rules come from Medicare.gov and CMS, re-read Nov. 12, 2026. We don’t suggest NexLife meets any plan’s therapy requirement.
  • Every fact, sourced. Each price and rule links to the page it comes from.
  • How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
  • Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
  • How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves

Plan won’t cover your GLP-1 in 2027? Here’s one option.

A 3-minute online check, then a licensed provider decides if compounded tirzepatide is right for you. It’s $115 a month on the 12-month plan, or $129 month to month, at every dose.

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified

Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.

  1. 1
    Tell us about you

    Start online with your health history.

  2. 2
    A licensed provider decides

    Online, following your state’s rules. You’re prescribed only if treatment is right for you.

  3. 3
    We ship it, then stay with you

    Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.

Sources

  1. OPM: Federal Benefits Open Season Highlights, 2027 plan year. Read Nov. 15, 2026.
  2. OPM Office of the Inspector General: FEHB Program trends, increases in GLP-1 spending from 2019 to 2024 (December 8, 2025). Read October 25, 2026.
  3. OPM: Postal Service Health Benefits (PSHB) Program carriers. Read November 1, 2026.
  4. FedSmith: 2027 FEHB changes, weight loss drug rules, a new FSA card and plans leaving (October 5, 2026). Read November 1, 2026.
  5. FedTools: Is FEHB charging 50% for GLP-1s in 2027? Not on every plan (October 21, 2026). Read November 15, 2026.
  6. Compass Rose Health Plan: 2027 FEHB plan benefits and changes (October 5, 2026). Read November 1, 2026.
  7. FEP Blue: What’s new for 2027. Read November 1, 2026.
  8. FEP Blue: Prescription drug coverage, 2027 tiers and drug cost tool. Read November 1, 2026.
  9. FEP Blue: 2027 FEP Blue Standard and FEP Blue Basic brochure (FEHB). Read November 1, 2026.
  10. FEP Blue: Formulary page, with links to the 2027 drug lists. Read November 1, 2026.
  11. FEP Blue Standard Formulary, effective January 1, 2027 (2027 Traditional Drug List, FEHB; PDF). Read November 1, 2026.
  12. FEP Blue Basic Formulary, effective January 1, 2027 (2027 Traditional Drug List, FEHB; PDF). Read November 1, 2026.
  13. FEP Blue Focus Drug Formulary, effective January 1, 2027 (2027 Traditional Drug List, FEHB; PDF). Read November 1, 2026.
  14. Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read November 15, 2026.
  15. NovoCare: Wegovy savings offer and self-pay terms. Read November 15, 2026.
  16. NovoCare Pharmacy: terms and self-pay prices. Read November 15, 2026.
  17. LillyDirect: Zepbound self-pay prices. Checked November 15, 2026.
  18. Eli Lilly: Zepbound savings and insurance options (the KwikPen self-pay card’s terms). Read November 15, 2026.
  19. Medicare.gov: Weight loss drugs (the Medicare GLP-1 Bridge). Read Nov. 15, 2026.
  20. Medicare.gov: How much does Medicare drug coverage cost?. Read November 15, 2026.
  21. FSAFEDS: What expenses are eligible for reimbursement from my HCFSA?. Read November 1, 2026.
  22. NexLife: GLP-1 price index. Compounded prices checked Nov. 15, 2026.
  23. NexLife: pricing, every plan.
  24. CMS: Medicare GLP-1 Bridge (page modified July 13, 2026). Read Nov. 15, 2026.
  25. CMS fact sheet: What’s the Medicare Prescription Payment Plan? (September 2026), the $2,400 out-of-pocket cap in 2027. Read Nov. 15, 2026.
  26. Eli Lilly: Zepbound (tirzepatide) prescribing information.
  27. FDA: Compounding and the FDA, questions and answers.